Bryn Mawr Capital Management LLC Has $3.41 Million Position in Zoetis Inc. (NYSE:ZTS)

Bryn Mawr Capital Management LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 25.0% in the 4th quarter, HoldingsChannel reports. The firm owned 20,902 shares of the company’s stock after acquiring an additional 4,178 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Zoetis were worth $3,406,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in Zoetis in the third quarter worth $31,000. First Personal Financial Services bought a new stake in shares of Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis during the 3rd quarter valued at $33,000. Finally, Dunhill Financial LLC grew its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Zoetis Price Performance

ZTS stock opened at $168.60 on Wednesday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The firm’s 50-day moving average price is $166.26 and its two-hundred day moving average price is $177.66. The stock has a market capitalization of $75.50 billion, a price-to-earnings ratio of 30.82, a PEG ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.19%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Morgan Stanley dropped their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $215.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.